tiprankstipranks
Sanofi, Regeneron’s Libtayo Delivers Positive Results In Pivotal Lung Cancer Trial
Market News

Sanofi, Regeneron’s Libtayo Delivers Positive Results In Pivotal Lung Cancer Trial

Sanofi (SNYNF) and Regeneron have announced positive pivotal trial data for the investigational use of PD-1 inhibitor Libtayo (cemiplimab) in first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

The trial compared Libtayo monotherapy to platinum-doublet chemotherapy in patients whose tumor cells expressed PD-L1, including those whose cancers had confirmed PD-L1 expression of ≥50%.

Lung cancer is the leading cause of cancer death worldwide, with more than 2.2 million new cases expected globally in 2020. Approximately 85% of all lung cancers are NSCLC, and an estimated 25% to 30% of these cases are expected to test positive for PD-L1 in ≥50% of tumor cells.

“In new analyses presented at ESMO, Libtayo reduced the risk of death by 43% in patients whose cancer had confirmed PD-L1 expression of 50% or greater. This is notable given that nearly three-quarters of patients crossed over from chemotherapy following disease progression and 12% of patients had pretreated and stable brain metastases,” said Ahmet Sezer, M.D., a trial investigator. 

“These results support Libtayo as a potential new option for anti-PD-1 monotherapy in first-line advanced non-small cell lung cancer” he added.

In the overall trial population (n=710), the median follow-up was 13 months for both Libtayo and chemotherapy. Among these patients, Libtayo demonstrated the following results compared to chemotherapy: 32% reduced risk of death; 22-month median overall survival compared to 14 months; 41% reduced risk of disease progression; median progression-free survival (PFS) of 6.2 months compared to 5.6 months; and a 37% objective response rate (ORR) compared to 21%.

A prespecified analysis of data from patients whose cancers had confirmed PD-L1 expression ≥50% (n=563) was also conducted. Here Libtayo demonstrated the following results vs chemotherapy: 43% reduced risk of death; 46% reduced risk of disease progression; the median PFS was 8 months vs 6 months; and 39% ORR vs 20% ORR.

The trial also found a direct correlation between tumor response and PD-L1 expression level in Libtayo-treated patients. The ORR was highest (46%; range: 36-56%) in tumors with ≥90% PD-L1 expression, with target tumors shrinking by more than 40% after 6 months of treatment on average (per last observation carried forward method). This correlation with PD-L1 expression level was not observed with chemotherapy.

Overall adverse events (AEs) occurred in 88% of Libtayo patients and 94% of chemotherapy patients. Grade 3 or higher AEs occurred in 37% of Libtayo patients and 49% of chemotherapy patients. No new Libtayo safety signals were observed.

Libtayo is a fully-human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells. By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation.

Turning to the Street, Sanofi shows a bullish Strong Buy Street consensus, while Regeneron (REGN) scores a slightly more cautious Moderate Buy consensus. Meanwhile the average analyst price target indicates roughly 20% upside potential lies ahead for both stocks. However Sanofi has only climbed 4.5% year-to-date, while Regeneron has exploded 48%.

“REGN is on the cusp of: (1) strong 20/21 sales growth, (2) increased Eylea penetration in DME in 2020/21; (3) approval, launch, and fast uptake of Dupixent in asthma/other allergic conditions; and (4) approval, launch, and fast uptake of Libtayo in advanced cSCC/other oncology indications” commented Oppenheimer’s Hartaj Singh recently.

He has a buy rating on the stock, adding “we continue to believe investors should own the three leaders (respectively) in the COVID-19 race; GILD, REGN, and MRNA.” (See REGN stock analysis on TipRanks).

Related News:
Eli Lilly’s Verzenio Treatment Lowers Breast Cancer Recurrence By 25%
Novavax Inks Deal With India For 2B Covid-19 Vaccine Doses In 2021
Merck Puts Focus On Lower Debt, Sees Smaller Takeovers After 2022

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles